Horizon 3 Healthcare Research
Investment Thesis
Horizon 3 Healthcare (H3 Healthcare, also referred to as Horizon 3 Biotech Fund) is a Melbourne, Australia-based specialist healthcare growth-equity investment firm. The firm positions itself as filling the gap between early-stage venture funding and late-stage global medtech capital. Its stated mandate is to invest in healthcare products with global growth potential across medical devices, drugs, digital health, and diagnostics, contributing capital, business excellence, deep commercialisation partnerships, and health science expertise to help portfolio companies translate strong science into better patient outcomes and investor returns. Horizon 3 targets an IRR of 20% per annum over a five-year timeframe (with the standard caveat that returns are not guaranteed).
Stage Focus
Horizon 3 is explicitly a growth-stage investor, not an early-stage or seed fund. The firm backs "companies with runs on the board" — meaning target companies typically have already achieved clinical validation and are revenue generating. This distinguishes it from typical biotech venture funds that back pre-clinical or early clinical-stage assets; H3 enters once technical and initial commercial risk has been substantially reduced.
Check Size
No specific check-size range is published on the firm's website or in available third-party sources. Given the growth-stage, de-risked profile of its targets (e.g., leading a €20.5M raise for Xeltis in mid-2026) and its history as a multi-fund vehicle backed by a CIO who previously ran a $200M FUM fund, checks are likely in the mid-single-digit-million-dollar-plus range, but this should be treated as directional rather than confirmed.
Lead Tendency
Horizon 3 has demonstrated a willingness to lead rounds — it was named as the new lead investor in Xeltis's €20.5M funding tranche in July 2026, alongside participation from existing investors including the European Investment Bank and Invest-NL.
Recent Activity
The firm's most significant recent activity is its July 2026 investment as new lead investor in Xeltis, a Netherlands-based medtech company developing aXess, a restorative bioresorbable vascular access conduit for hemodialysis patients with end-stage renal disease. The round was intended to advance aXess toward FDA approval and US commercial launch, following Xeltis's first commercial implants and European launch earlier in 2026. This is the firm's first publicly reported new investment of 2026 after a period with no new deals reported earlier in the year, consistent with a growth-stage fund that writes concentrated, larger checks rather than a high-velocity seed program.
Portfolio Highlights
Horizon 3's active and historical portfolio spans cardiac devices, ocular disease treatment, remote patient monitoring implants, ophthalmology, drug delivery, and neurological drug therapies:
- LumiThera — developing photobiomodulation treatments for ocular diseases and disorders.
- Cardiac Dimensions — devices and therapies to improve outcomes for heart failure patients.
- Canary Medical — implantable sensor technology (Canturio and Summatix products) that allows medical implants to self-report patient data, supporting remote patient monitoring reimbursement pathways.
- Xeltis — restorative, bioresorbable vascular access and cardiovascular implants (new 2026 investment).
Exits:
- Volpara Health Technologies — AI-powered breast cancer screening software; agreed to be acquired by Lunit in January 2024 for approximately US$193M, with the deal completing in May 2024.
- Neuren Pharmaceuticals (ASX: NEU) — developer of trofinetide (DAYBUE), FDA-approved for Rett syndrome and licensed exclusively to Acadia Pharmaceuticals; Horizon 3 exited its position in November 2024.
- EBR Systems — developer of the WiSE CRT System, a wireless technology for left-ventricular pacing in heart failure patients.
- Avecho — developer of TPM (tocopheryl phosphate mixture), a proprietary Vitamin E-based drug delivery platform.
Across its lifetime the firm has been reported (via Tracxn) as having invested in roughly seven to eight companies since founding in 2020.
Team
Horizon 3 is led by CIO Matt McNamara, a molecular biologist by training with an MBA and over 30 years in healthcare/medical sciences, including 14 years as CIO of BioScience Managers (4 funds, ~$200M FUM, >20% IRR) and CEO of SciCapital's pre-seed fund. Horizon 3 is described as Matt's fifth fund over more than 20 years, with prior funds delivering top-quartile returns and backing three unicorns.
The firm operates with both an Investment Committee and a Board:
- Investment Committee: Matt McNamara (CIO); Dr Bev Thomas (Senior Investment Professional, CEO of Syntro Health); Dr Qibing Mei (pharmacologist, Chief Scientist at HK Biotech); Scott Power (Investment Analyst, Senior Analyst at Morgans Financial covering ASX healthcare/life science stocks).
- Board: Matt McNamara (Board Director); Mike Sullivan (Board Executive Chairman and co-founder, ex-National Australia Bank and Ferris Baker Watts banking/capital-markets executive); Jian Sun (Board Director, founder of Huikang Bio-Tech/HK Biotechnology in China); Glenn Cross (Board Director, former COO/CEO of AusBiotech, now runs Red Bluff Capital); Robin Chambers AO (Board Director, corporate lawyer and advisor); Assoc Prof Tam Nguyen (Non-Executive Director and Deputy Director of Research, Director of Research and Innovation at Monash Health); Claire Newstead-Sinclair (Company Secretary).
Decision Process
Decisions run through a formal Investment Committee (four named members) with Board oversight, consistent with an institutional investment-committee process rather than a solo-GP or informal partnership structure.
Founder Preferences
The firm is explicit that it is not a typical early-stage biotech venture investor: it seeks growth-stage healthcare companies with proven clinical validation and existing revenue, run by teams that have already de-risked the core science and are executing on commercialisation, expansion, or regulatory milestones (e.g., FDA approval pathways).
Geographic Focus
Horizon 3 is headquartered in Melbourne, Australia, but invests globally — its active and exited portfolio includes companies headquartered in the US (Cardiac Dimensions, Canary Medical, EBR Systems, LumiThera), Australia (Avecho, Neuren Pharmaceuticals), and continental Europe (Xeltis, Netherlands).